JP2022513804A - 組織癒着を防止するための低濃縮タンパク質組成物 - Google Patents
組織癒着を防止するための低濃縮タンパク質組成物 Download PDFInfo
- Publication number
- JP2022513804A JP2022513804A JP2021533575A JP2021533575A JP2022513804A JP 2022513804 A JP2022513804 A JP 2022513804A JP 2021533575 A JP2021533575 A JP 2021533575A JP 2021533575 A JP2021533575 A JP 2021533575A JP 2022513804 A JP2022513804 A JP 2022513804A
- Authority
- JP
- Japan
- Prior art keywords
- fibrinogen
- thrombin
- component
- total protein
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 100
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 100
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 208000031737 Tissue Adhesions Diseases 0.000 title claims abstract description 29
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 243
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 243
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 243
- 108090000190 Thrombin Proteins 0.000 claims abstract description 133
- 229960004072 thrombin Drugs 0.000 claims abstract description 133
- 239000000017 hydrogel Substances 0.000 claims abstract description 73
- 108010088751 Albumins Proteins 0.000 claims abstract description 70
- 102000009027 Albumins Human genes 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 68
- 239000000463 material Substances 0.000 claims abstract description 41
- 108010073385 Fibrin Proteins 0.000 claims abstract description 39
- 102000009123 Fibrin Human genes 0.000 claims abstract description 39
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229950003499 fibrin Drugs 0.000 claims abstract description 39
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 20
- 238000001356 surgical procedure Methods 0.000 claims description 29
- 239000002244 precipitate Substances 0.000 claims description 21
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 230000000181 anti-adherent effect Effects 0.000 claims description 16
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 16
- 229960000401 tranexamic acid Drugs 0.000 claims description 16
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 15
- 108010039627 Aprotinin Proteins 0.000 claims description 13
- 229960004405 aprotinin Drugs 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000005507 spraying Methods 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 208000031220 Hemophilia Diseases 0.000 claims description 5
- 208000009292 Hemophilia A Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 description 83
- 210000001519 tissue Anatomy 0.000 description 60
- 241001465754 Metazoa Species 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 20
- 229960005069 calcium Drugs 0.000 description 20
- 239000011575 calcium Substances 0.000 description 20
- 229910052791 calcium Inorganic materials 0.000 description 20
- 210000002381 plasma Anatomy 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 230000015271 coagulation Effects 0.000 description 14
- 238000005345 coagulation Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000504 antifibrinolytic agent Substances 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 6
- 108010054218 Factor VIII Proteins 0.000 description 6
- 102000001690 Factor VIII Human genes 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000012084 abdominal surgery Methods 0.000 description 6
- 229960000301 factor viii Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 108010071289 Factor XIII Proteins 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229960002713 calcium chloride Drugs 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 229940012444 factor xiii Drugs 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 102000013566 Plasminogen Human genes 0.000 description 4
- 108010051456 Plasminogen Proteins 0.000 description 4
- 229960003589 arginine hydrochloride Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 4
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 4
- 238000013130 cardiovascular surgery Methods 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000013024 dilution buffer Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000000535 fibrinogen concentrate Substances 0.000 description 4
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 108010047303 von Willebrand Factor Proteins 0.000 description 4
- 102100036537 von Willebrand factor Human genes 0.000 description 4
- 229960001134 von willebrand factor Drugs 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 108010031318 Vitronectin Proteins 0.000 description 3
- 102100035140 Vitronectin Human genes 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 3
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000000665 Cohn process Methods 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010060932 Postoperative adhesion Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940033618 tisseel Drugs 0.000 description 2
- 239000003106 tissue adhesive Substances 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 241000396836 Trinodes Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000007486 appendectomy Methods 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- -1 but not limited to Chemical class 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000003715 calcium chelating agent Substances 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000012820 exploratory laparotomy Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 229940049321 pentobarbital sodium 390 mg/ml Drugs 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940101909 phenytoin sodium 50 mg/ml Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/366—Thrombomodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/046—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本開示は、フィブリノーゲン及びトロンビンを含むキット、並びに組織癒着を低減及び防止するためのその使用に関する。
本開示の主題の背景として関連性があると見なされる参照文献を以下に列記する。
-国際公開第9855140号
-米国特許第6,965,014号
-米国特許出願公開第2002/001584号
-米国特許第6,613,325号
-Wiseman et al., The effect of tranexamic acid in fibrin sealant on adhesion formation in the rat.J. Biomed.Mater.Res.B Appl. Biomater.(2004); 68(2): 222-30。
実施例:様々な条件下での保水
この研究は、様々な製剤を使用して形成された凝固における保水率(%)を定量し、保水率(%)に対するアルブミンの効果を評価することを目的とした。各実験は、本明細書でフィブリノーゲン成分及びトロンビン成分として示される2つの異なる成分を組み合わせる(各成分0.5mL)ことを含んだ。
ヒドロゲル形成の1~2時間後に、保水率(%)を、周囲条件下で評価した(ヒドロゲル形成は目視検査により判定した)。ヒドロゲル形成後1時間~最大2時間後に、表面積は約1cm2で30分間、セントリコンチューブ内で1mLのヒドロゲルを630gの穏やかな遠心分離にかけ、ヒドロゲル中の保持水の量を評価した。表4は、異なる凝固の保水能力の結果を要約している。
ヒドロゲル形成後すぐに、ヒドロゲルの保水率(%)を、高圧条件下で評価した(ヒドロゲル形成は目視検査により判定した)。ヒドロゲル形成後、1mLのヒドロゲルを、エッペンドルフチューブ0.7~1cm2中で、31,514g(約457PSIの圧力)で30分間遠心分離し、ヒドロゲル中の保持水の量を評価した。表5は、異なるヒドロゲルの保水能力の結果を要約している。
この研究の目的は、ウサギ子宮角癒着モデルにおける、異なる濃度のフィブリノーゲン及びアルブミンを有する様々な製剤の有効性を特徴付けることであった。
試験システム
若年/若年成人(手術時13~15週齢)雌ニュージーランド白色ウサギ(Oryctolagus cuniculus)を研究に使用した。ウサギは、Western Oregon Rabbit Co.(PO Box 653, Philomath, OR USA)から入手し、供給元によって適用された固有の耳タグによって個別に識別した。
試験施設に到着した直後に、経験豊富な動物管理担当者によって動物を検査した。
動物を個別にステンレス鋼ケージに収容し、それぞれ研究番号及び個々の動物番号を示す個別のカードで標識した。室内環境を、約68°F(約20℃)、相対湿度30~70%、及び12時間/12時間の光/暗サイクルで維持した。
ウサギの子宮角単純擦過モデルは、本質的にWiseman 1992(Effect of thrombin induced hemostasis on the efficacy of an absorbable adhesion barrier. The journal of reproductive medicine vol 37 No 9, September 1992)に記載されているように実施される。
癒着の程度及び発生率:癒着のある各子宮角の長さを推定する。結果は、癒着の発生率(癒着を伴う子宮角の数/総数)及び癒着の程度(癒着を伴う子宮角の長さ%)として表される。
・回旋なし:癒着した又は癒着していない子宮角の直線長さがはっきりと見える。
・部分的な回旋:子宮角には癒着があり、子宮角の長さの50%~75%が絡み合い直線部分の識別を妨げる。
・完全に回旋子宮:角が完全に絡み合っているため、子宮の解剖学的構造を見ることは不可能である。
2 対照に対するスチューデントt検定のp値
3 癒着のない子宮角の%(癒着のない子宮角の数/総数)
4 癒着なし/等級1癒着/等級2癒着を有する子宮角の数
5 回旋なし/部分的な回旋/完全な回旋を有する子宮角の数
* p<0.05ダネットのt検定対対照
# p値χ2試験,対対照)。<0.1の値のみを示す。
(1) キットであって、
(i)約5mg/mL~約30mg/mLの濃度範囲のフィブリノーゲンを含み、約15mg/mL~約40mg/mLの総タンパク質濃度範囲を有するフィブリノーゲン含有成分の溶液を含む第1の容器と、
(ii)トロンビン含有成分の溶液を含む第2の容器と、を備える、キット。
(2) 前記フィブリノーゲン含有成分が、トラネキサム酸又はアプロチニンを含まない、実施態様1に記載のキット。
(3) 前記フィブリノーゲン含有成分が、約20mg/mL~約40mg/mLの濃度範囲の総タンパク質を含む、実施態様1又は2に記載のキット。
(4) 前記フィブリノーゲン含有成分が、約8mg/mL~約25mg/mLの濃度範囲のフィブリノーゲンを含む、実施態様1~3のいずれかに記載のキット。
(5) 前記フィブリノーゲン含有成分が、約10mg/mL~約25mg/mLの濃度範囲のフィブリノーゲンと、約20mg/mL~約40mg/mLの総タンパク質濃度と、を含む、実施態様1~4のいずれかに記載のキット。
(7) 前記フィブリノーゲン含有成分が、20重量%未満の濃度範囲のアルブミンを含む、実施態様1~6のいずれかに記載のキット。
(8) 前記フィブリノーゲン含有成分及び/又は前記トロンビン含有成分が、遊離カルシウムイオンを含む、実施態様1~7のいずれかに記載のキット。
(9) 前記フィブリノーゲンが、血漿寒冷沈降反応によって得られる、実施態様1~8のいずれかに記載のキット。
(10) 前記フィブリノーゲンが、生物的に活性な構成成分2(BAC2)に由来する、実施態様1~8のいずれかに記載のキット。
(12) 前記フィブリノーゲン含有成分及び/又は前記トロンビン含有成分が、液体又は凍結形態である、実施態様1~11のいずれかに記載のキット。
(13) 組織癒着の防止/低減に使用するための使用説明書を含む、実施態様1~12のいずれかに記載のキット。
(14) 抗癒着混合物の製造に使用するための、実施態様1~12のいずれかに記載のキット。
(15) 侵襲的処置後の組織癒着の防止/低減に使用するための、実施態様13及び14のいずれかに記載のキット。
(17) 前記溶液を組織に噴霧又は滴下することによって投与される、実施態様1~16のいずれかに記載のキット。
(18) 前記第1の容器及び/又は前記第2の容器が、アプリケータである、実施態様1~17のいずれかに記載のキット。
(19) 前記アプリケータが、シリンジである、実施態様18に記載のキット。
(20) フィブリノーゲン、トロンビン、カルシウムイオン、及びアルブミンを含む混合物であって、前記混合物が、約2.5mg/mL~約30mg/mLの範囲の総タンパク質と、総タンパク質の約50重量%~約80重量%の範囲のフィブリノーゲンと、0.65mg/mL超~約3mg/mLの範囲のアルブミンと、を含む、混合物。
(22) フィブリン及びカルシウムイオンを含むヒドロゲル材料であって、前記総タンパク質濃度が約2.5mg/mL~約30mg/mLの範囲であり、前記フィブリンは、総タンパク質の50~80重量%の濃度範囲で存在する、ヒドロゲル材料。
(23) 前記ヒドロゲル材料が、0.65mg/mL超~約3mg/mLの範囲のアルブミンを更に含む、実施態様22に記載のヒドロゲル材料。
(24) 前記アルブミンが、約1.2mg/mL~約3mg/mLの範囲である、実施態様22又は23に記載のヒドロゲル材料。
(25) 前記総タンパク質濃度範囲が、約7.5mg/mL~約20mg/mLである、実施態様22~24のいずれかに記載のヒドロゲル材料。
(27) 抗癒着特性を有する、実施態様22~26のいずれかに記載のヒドロゲル材料。
(28) ヒドロゲル材料であって、ヒドロゲルの形成を可能にする条件下で、(i)約5mg/mL~約30mg/mLの濃度範囲のフィブリノーゲンと、約15mg/mL~約40mg/mLの総タンパク質濃度範囲と、を含み、前記フィブリノーゲンが、総タンパク質の約50重量%~約80重量%の範囲である、フィブリノーゲン含有溶液と、(ii)トロンビン含有溶液と、を含む混合物を、組織上に適用することによって得られる、架橋フィブリンを含む、ヒドロゲル材料。
(29) 前記混合物が、エックスビボで前記フィブリノーゲン含有溶液と前記トロンビン含有溶液とを組み合わせることによって得られる、実施態様28に記載のヒドロゲル材料。
(30) 組織癒着の防止に使用するための2成分組成物であって、
成分Aであって、約5mg/mL~約30mg/mLの濃度範囲のフィブリノーゲンと、約15mg/mL~約40mg/mLの総タンパク質濃度範囲と、を含み、前記フィブリノーゲンが、総タンパク質の約50重量%~約80重量%の範囲である、フィブリノーゲン含有溶液を含む、成分Aと、トロンビンを含む成分Bと、を含む、2成分組成物。
(32) 前記成分Bが、約100IU/mL~約300IU/mLの濃度範囲のトロンビンを含む、実施態様30又は31に記載の2成分組成物。
(33) 成分A及び/又は成分Bが、遊離カルシウムイオンを含む、実施態様30~32のいずれかに記載の2成分組成物。
(34) 組織癒着を防止又は低減する方法であって、前記方法は、フィブリノーゲン含有成分及びトロンビン含有成分を、被験体の前記組織の少なくとも一部に適用することを含み、前記フィブリノーゲン含有成分が、約15mg/mL~約40mg/mLの範囲の総タンパク質濃度と、約5mg/mL~約30mg/mLの濃度範囲のフィブリノーゲンと、を含み、前記フィブリノーゲンが、総タンパク質の約50重量%~約80重量%の範囲である、方法。
(35) フィブリノーゲン含有成分及びトロンビン含有成分を、被験体の前記組織の少なくとも一部に同時に適用することを含む、実施態様34に記載の方法。
(37) 適用することが、噴霧若しくは滴下噴霧、スミアリング、ブラッシング、又は注入を含む、実施態様34~36のいずれかに記載の方法。
(38) 前記組織が、創傷組織であり、前記方法が、侵襲的処置中の組織癒着を防止するためのものである、実施態様34~37のいずれかに記載の方法。
(39) 前記侵襲的処置が、外科的処置である、実施態様38に記載の方法。
(40) 前記外科的処置が、腹部手術、心臓血管手術、胸部手術、頭部及び頸部手術、骨盤手術、皮膚及び皮下組織処置のうちの少なくとも1つである、実施態様39に記載の方法。
(42) 前記被験体が、ヒト被験体である、実施態様34~41のいずれかに記載の方法。
(43) 前記フィブリノーゲン含有成分が、約15mg/mL~約40mg/mLの濃度範囲の総タンパク質と、約8mg/mL~約25mg/mLの濃度範囲のフィブリノーゲンと、を含む、実施態様34~42のいずれかに記載の方法。
(44) 前記トロンビン含有成分が、約100IU/mL~約300IU/mLの濃度範囲のトロンビンを含む、実施態様34~43のいずれかに記載の方法。
(45) 前記フィブリノーゲン含有成分及び/又は前記トロンビン含有成分が、遊離カルシウムイオンを含む、実施態様34~44のいずれかに記載の方法。
Claims (33)
- キットであって、
(i)約5mg/mL~約30mg/mLの濃度範囲のフィブリノーゲンを含み、約15mg/mL~約40mg/mLの総タンパク質濃度範囲を有するフィブリノーゲン含有成分の溶液を含む第1の容器と、
(ii)トロンビン含有成分の溶液を含む第2の容器と、を備える、キット。 - 前記フィブリノーゲン含有成分が、トラネキサム酸又はアプロチニンを含まない、請求項1に記載のキット。
- 前記フィブリノーゲン含有成分が、約20mg/mL~約40mg/mLの濃度範囲の総タンパク質を含む、請求項1又は2に記載のキット。
- 前記フィブリノーゲン含有成分が、約8mg/mL~約25mg/mLの濃度範囲のフィブリノーゲンを含む、請求項1~3のいずれか一項に記載のキット。
- 前記フィブリノーゲン含有成分が、約10mg/mL~約25mg/mLの濃度範囲のフィブリノーゲンと、約20mg/mL~約40mg/mLの総タンパク質濃度と、を含む、請求項1~4のいずれか一項に記載のキット。
- 前記トロンビン含有成分が、約100IU/mL~約300IU/mLの濃度範囲のトロンビンを含む、請求項1~5のいずれか一項に記載のキット。
- 前記フィブリノーゲン含有成分が、20重量%未満の濃度範囲のアルブミンを含む、請求項1~6のいずれか一項に記載のキット。
- 前記フィブリノーゲン含有成分及び/又は前記トロンビン含有成分が、遊離カルシウムイオンを含む、請求項1~7のいずれか一項に記載のキット。
- 前記フィブリノーゲンが、血漿寒冷沈降反応によって得られる、請求項1~8のいずれか一項に記載のキット。
- 前記フィブリノーゲンが、生物的に活性な構成成分2(BAC2)に由来する、請求項1~8のいずれか一項に記載のキット。
- 前記フィブリノーゲンが、抗血友病因子調製物に由来する血漿寒冷沈降物の生物的に活性な構成成分である、請求項1~9のいずれか一項に記載のキット。
- 前記フィブリノーゲン含有成分及び/又は前記トロンビン含有成分が、液体又は凍結形態である、請求項1~11のいずれか一項に記載のキット。
- 組織癒着の防止/低減に使用するための使用説明書を含む、請求項1~12のいずれか一項に記載のキット。
- 抗癒着混合物の製造に使用するための、請求項1~12のいずれか一項に記載のキット。
- 侵襲的処置後の組織癒着の防止/低減に使用するための、請求項13及び14のいずれか一項に記載のキット。
- 前記侵襲的処置が、外科的処置又は診断処置である、請求項15に記載のキット。
- 前記溶液を組織に噴霧又は滴下することによって投与される、請求項1~16のいずれか一項に記載のキット。
- 前記第1の容器及び/又は前記第2の容器が、アプリケータである、請求項1~17のいずれか一項に記載のキット。
- 前記アプリケータが、シリンジである、請求項18に記載のキット。
- フィブリノーゲン、トロンビン、カルシウムイオン、及びアルブミンを含む混合物であって、前記混合物が、約2.5mg/mL~約30mg/mLの範囲の総タンパク質と、総タンパク質の約50重量%~約80重量%の範囲のフィブリノーゲンと、0.65mg/mL超~約3mg/mLの範囲のアルブミンと、を含む、混合物。
- 前記アルブミンが、約1.20mg/mL~約3mg/mLの範囲内である、請求項20に記載の混合物。
- フィブリン及びカルシウムイオンを含むヒドロゲル材料であって、前記総タンパク質濃度が約2.5mg/mL~約30mg/mLの範囲であり、前記フィブリンは、総タンパク質の50~80重量%の濃度範囲で存在する、ヒドロゲル材料。
- 前記ヒドロゲル材料が、0.65mg/mL超~約3mg/mLの範囲のアルブミンを更に含む、請求項22に記載のヒドロゲル材料。
- 前記アルブミンが、約1.2mg/mL~約3mg/mLの範囲である、請求項22又は23に記載のヒドロゲル材料。
- 前記総タンパク質濃度範囲が、約7.5mg/mL~約20mg/mLである、請求項22~24のいずれか一項に記載のヒドロゲル材料。
- 前記フィブリンが、架橋フィブリンである、請求項22又は25に記載のヒドロゲル材料。
- 抗癒着特性を有する、請求項22~26のいずれか一項に記載のヒドロゲル材料。
- ヒドロゲル材料であって、ヒドロゲルの形成を可能にする条件下で、(i)約5mg/mL~約30mg/mLの濃度範囲のフィブリノーゲンと、約15mg/mL~約40mg/mLの総タンパク質濃度範囲と、を含み、前記フィブリノーゲンが、総タンパク質の約50重量%~約80重量%の範囲である、フィブリノーゲン含有溶液と、(ii)トロンビン含有溶液と、を含む混合物を、組織上に適用することによって得られる、架橋フィブリンを含む、ヒドロゲル材料。
- 前記混合物が、エックスビボで前記フィブリノーゲン含有溶液と前記トロンビン含有溶液とを組み合わせることによって得られる、請求項28に記載のヒドロゲル材料。
- 組織癒着の防止に使用するための2成分組成物であって、
成分Aであって、約5mg/mL~約30mg/mLの濃度範囲のフィブリノーゲンと、約15mg/mL~約40mg/mLの総タンパク質濃度範囲と、を含み、前記フィブリノーゲンが、総タンパク質の約50重量%~約80重量%の範囲である、フィブリノーゲン含有溶液を含む、成分Aと、トロンビンを含む成分Bと、を含む、2成分組成物。 - 前記フィブリノーゲン含有溶液が、約10mg/mL~約25mg/mLの濃度範囲のフィブリノーゲンと、約20mg/mL~約40mg/mLの範囲の総タンパク質濃度と、を含む、請求項30に記載の2成分組成物。
- 前記成分Bが、約100IU/mL~約300IU/mLの濃度範囲のトロンビンを含む、請求項30又は31に記載の2成分組成物。
- 成分A及び/又は成分Bが、遊離カルシウムイオンを含む、請求項30~32のいずれか一項に記載の2成分組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024037064A JP2024056090A (ja) | 2018-12-12 | 2024-03-11 | 組織癒着を防止するための低濃縮タンパク質組成物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862778331P | 2018-12-12 | 2018-12-12 | |
IL263679A IL263679A (en) | 2018-12-12 | 2018-12-12 | Kits, methods, and ingredients for preventing tissue adhesion |
US62/778,331 | 2018-12-12 | ||
IL263679 | 2018-12-12 | ||
PCT/IL2019/000004 WO2020121289A1 (en) | 2018-12-12 | 2019-12-11 | Low concentrated protein compositions for preventing tissue adhesion |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024037064A Division JP2024056090A (ja) | 2018-12-12 | 2024-03-11 | 組織癒着を防止するための低濃縮タンパク質組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022513804A true JP2022513804A (ja) | 2022-02-09 |
JP7455838B2 JP7455838B2 (ja) | 2024-03-26 |
Family
ID=65910765
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021533575A Active JP7455838B2 (ja) | 2018-12-12 | 2019-12-11 | 組織癒着を防止するための低濃縮タンパク質組成物 |
JP2024037064A Pending JP2024056090A (ja) | 2018-12-12 | 2024-03-11 | 組織癒着を防止するための低濃縮タンパク質組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024037064A Pending JP2024056090A (ja) | 2018-12-12 | 2024-03-11 | 組織癒着を防止するための低濃縮タンパク質組成物 |
Country Status (7)
Country | Link |
---|---|
US (3) | US11918629B2 (ja) |
EP (2) | EP3893911A1 (ja) |
JP (2) | JP7455838B2 (ja) |
CN (2) | CN113194974A (ja) |
AU (2) | AU2019396756A1 (ja) |
CA (1) | CA3122456A1 (ja) |
IL (3) | IL263679A (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL263679A (en) * | 2018-12-12 | 2019-03-31 | Omrix Biopharmaceuticals Ltd | Kits, methods, and ingredients for preventing tissue adhesion |
CN114452442A (zh) * | 2022-01-30 | 2022-05-10 | 上海松力生物技术有限公司 | 一种原位诱导子宫壁组织再生的植入物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11502431A (ja) * | 1995-01-16 | 1999-03-02 | バクスター インターナショナル インコーポレイテッド | 手術後の癒着を防止するための架橋化フィブリンの自己支持シート様材料 |
EP1695724A1 (en) * | 2001-05-09 | 2006-08-30 | Baxter International Inc. | Fibrin material and method for producing and using the same |
JP2010531870A (ja) * | 2007-07-02 | 2010-09-30 | オムリックス・バイオファーマシューティカルズ・リミテッド | 酵素的に許容される量の可視化剤を有するキット、製剤および溶液、ならびにそれらの使用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2390074A (en) | 1942-02-09 | 1945-12-04 | Research Corp | Protein product and process |
DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
US4455300A (en) | 1980-03-05 | 1984-06-19 | Cutter Laboratories, Inc. | Fibronectin compositions |
EP0534178B1 (en) | 1991-09-27 | 2001-04-18 | Omrix Biopharmaceuticals S.A. | Improved tissue glue prepared by using cryoprecipitate |
WO1993005822A1 (en) * | 1991-09-27 | 1993-04-01 | Octapharma Ag | Tissue glue prepared by using cryoprecipitate |
US6965014B1 (en) | 1996-01-16 | 2005-11-15 | Baxter International Inc. | Fibrin material and method for producing and using the same |
US6121232A (en) | 1997-01-31 | 2000-09-19 | Omrix Biopharmaceuticals Sa | Stabilized mixture comprising fibrinogen |
EP0856317A1 (en) | 1997-01-31 | 1998-08-05 | Omrix Biopharmaceuticals S.A. | A stabilized mixture comprising fibrinogen |
WO1998055140A1 (en) | 1997-06-05 | 1998-12-10 | Omrix Biopharmaceuticals S.A. | Fibrinogen concentrate from human plasma |
DE10025001A1 (de) | 2000-05-22 | 2001-11-29 | Aventis Behring Gmbh | Gewebekleber mit verbesserten anti-adhäsiven Eigenschaften |
US7276235B2 (en) * | 1998-11-18 | 2007-10-02 | Zlb Behring Gmbh | Tissue glue with improved antiadhesive properties |
CA2373704A1 (en) | 1999-06-01 | 2000-12-07 | Bristol-Myers Squibb Company | Prevention of post surgical adhesions using a fibrin monomer sealant |
WO2002095019A1 (en) | 2001-05-21 | 2002-11-28 | Omrix Biopharmaceuticals S.A. | Removal of plasmin(ogen) from protein solutions |
CN1606447A (zh) * | 2001-10-03 | 2005-04-13 | 克里斯托弗·J·伍尔弗顿 | 保存稳定的纤维蛋白原溶液 |
CN101516301B (zh) * | 2006-08-04 | 2014-10-15 | Stb有限公司 | 用于处理受伤组织的固体敷料 |
US20180117210A1 (en) * | 2006-08-04 | 2018-05-03 | Stb, Ltd. | Solid dressing for treating wounded tissue and processes for mixing fibrinogen and thrombin while preserving fibrin-forming ability, compositions produced by these processes, and the use thereof |
JP5539332B2 (ja) * | 2008-05-22 | 2014-07-02 | エシコン・インコーポレイテッド | タンパク質アッセイ |
IL213864A0 (en) | 2011-06-30 | 2011-08-31 | Omrix Biopharmaceuticals Ltd | Method for removing a lytic enzyme from a heterogeneous mixture |
US9446166B2 (en) * | 2013-01-24 | 2016-09-20 | Ethicon, Inc. | Fibrin sealant compositions with chemical crosslinking |
IL242984A0 (en) * | 2015-12-08 | 2016-02-29 | Omrix Biopharmaceuticals Ltd | Thrombin microcapsules, their preparation and how to use them |
IL263679A (en) * | 2018-12-12 | 2019-03-31 | Omrix Biopharmaceuticals Ltd | Kits, methods, and ingredients for preventing tissue adhesion |
-
2018
- 2018-12-12 IL IL263679A patent/IL263679A/en unknown
-
2019
- 2019-12-11 US US16/710,541 patent/US11918629B2/en active Active
- 2019-12-11 EP EP19828327.7A patent/EP3893911A1/en active Pending
- 2019-12-11 EP EP19828326.9A patent/EP3893910A1/en active Pending
- 2019-12-11 JP JP2021533575A patent/JP7455838B2/ja active Active
- 2019-12-11 CN CN201980082780.XA patent/CN113194974A/zh active Pending
- 2019-12-11 CA CA3122456A patent/CA3122456A1/en active Pending
- 2019-12-11 CN CN201980082781.4A patent/CN113194975A/zh active Pending
- 2019-12-11 AU AU2019396756A patent/AU2019396756A1/en active Pending
- 2019-12-11 AU AU2019395933A patent/AU2019395933A1/en active Pending
- 2019-12-11 US US16/710,521 patent/US11583573B2/en active Active
-
2021
- 2021-06-08 IL IL283805A patent/IL283805A/en unknown
- 2021-06-08 IL IL283802A patent/IL283802A/en unknown
-
2023
- 2023-01-12 US US18/096,087 patent/US20230158119A1/en active Pending
-
2024
- 2024-03-11 JP JP2024037064A patent/JP2024056090A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11502431A (ja) * | 1995-01-16 | 1999-03-02 | バクスター インターナショナル インコーポレイテッド | 手術後の癒着を防止するための架橋化フィブリンの自己支持シート様材料 |
EP1695724A1 (en) * | 2001-05-09 | 2006-08-30 | Baxter International Inc. | Fibrin material and method for producing and using the same |
JP2010531870A (ja) * | 2007-07-02 | 2010-09-30 | オムリックス・バイオファーマシューティカルズ・リミテッド | 酵素的に許容される量の可視化剤を有するキット、製剤および溶液、ならびにそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
US11918629B2 (en) | 2024-03-05 |
IL263679A (en) | 2019-03-31 |
IL283802A (en) | 2021-07-29 |
US20200188489A1 (en) | 2020-06-18 |
AU2019395933A1 (en) | 2021-06-17 |
IL283805A (en) | 2021-07-29 |
JP2024056090A (ja) | 2024-04-19 |
US20200188488A1 (en) | 2020-06-18 |
JP7455838B2 (ja) | 2024-03-26 |
CN113194974A (zh) | 2021-07-30 |
CA3122456A1 (en) | 2020-06-18 |
CN113194975A (zh) | 2021-07-30 |
EP3893911A1 (en) | 2021-10-20 |
US20230158119A1 (en) | 2023-05-25 |
EP3893910A1 (en) | 2021-10-20 |
US11583573B2 (en) | 2023-02-21 |
AU2019396756A1 (en) | 2021-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6868314B2 (ja) | ヒアルロン酸−カルシウム及びポリリシンを含む創傷被覆材及びその製造方法 | |
US20180093010A1 (en) | Kits, formulations and solutions having enzymatically- permissive amounts of visualization agents and uses thereof | |
Petersen et al. | A comparison between 2 absorbable hemostatic agents: gelatin sponge (Spongostan®) and oxidized regenerated cellulose (Surgicel®) | |
JP2024056090A (ja) | 組織癒着を防止するための低濃縮タンパク質組成物 | |
JP2002531533A (ja) | 止血用コラーゲンフォーム | |
WO1996040033A1 (en) | Non-biological patch for hemostasis | |
BR112018009306B1 (pt) | Composição de fibras e/ou agregados hemostáticos à base de celulose, método de fabricação, gel, e método para formação de um gel | |
US20150125440A1 (en) | Method for improved fibrin sealing | |
Sinha et al. | Chitosan based Axiostat dental dressing following extraction in cardiac patients under antiplatelet therapy | |
WO2020121289A1 (en) | Low concentrated protein compositions for preventing tissue adhesion | |
WO2017060821A1 (en) | Hemostatic composition | |
JP4733283B2 (ja) | 液状フィブリノゲン製剤 | |
Naser et al. | Efficacy of local haemostatic agent following minor surgery (an experimental and clinical study) | |
RU2789967C1 (ru) | Способ клеевой фиксации септальных лоскутов слизистой оболочки в хоане у пациентов при хоанопластике | |
Abo-Ghanema et al. | Preparation of fibrin glue from catfish blood and its application | |
WO2019093505A1 (ja) | 癒着防止用組成物 | |
Abo-Ghanema et al. | PREPARATION OF FIBRIN GLUE FROM CATFISH (CLARIAS GARIEPINUS) BLOOD AND ITS APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221116 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230823 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231201 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240213 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240313 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7455838 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |